Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Lessons learned from genetic testing.

Esserman L, Kaklamani V.

JAMA. 2010 Sep 1;304(9):1011-2. doi: 10.1001/jama.2010.1263. No abstract available.

PMID:
20810382
2.

Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.

Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM.

Ann Surg Oncol. 2002 Dec;9(10):941-3. No abstract available.

PMID:
12464584
3.

Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.

Pasini B, Pierotti MA.

Dis Markers. 1999 Oct;15(1-3):41-3. No abstract available.

4.

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C.

JAMA. 1997 Mar 26;277(12):997-1003. Review.

PMID:
9091675
5.

[Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].

Narod SA, Rodríguez AA.

Salud Publica Mex. 2011 Sep-Oct;53(5):420-9. Review. Spanish.

6.

Using genetic analysis to individualize preventive measures for breast and ovarian cancers.

Olopade OI.

Nat Clin Pract Oncol. 2006 Apr;3(4):182-3. No abstract available.

PMID:
16596140
7.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
8.

Re: Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation carriers.

Foulkes WD.

J Natl Cancer Inst. 2003 Sep 3;95(17):1344; author reply 1344. No abstract available.

PMID:
12953090
9.

One risk fits all?

De Bock GH, Mourits MJ, Oosterwijk JC.

J Clin Oncol. 2007 Aug 1;25(22):3383-4; author reply 3384. No abstract available.

PMID:
17664491
10.

Counseling the at risk patient in the BRCA1 and BRCA2 Era.

Barnes-Kedar IM, Plon SE.

Obstet Gynecol Clin North Am. 2002 Jun;29(2):341-66, vii. Review.

PMID:
12108833
11.

Prophylactic mastectomy: why and when?

von Smitten K.

J Br Menopause Soc. 2003 Dec;9(4):151-5. Review.

PMID:
15107257
12.
13.

BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.

Miller-Samuel S, Rosenberg A, Berger A, Gomella L, Loren D, Morris GJ.

Semin Oncol. 2011 Oct;38(5):605-11. doi: 10.1053/j.seminoncol.2011.04.009. No abstract available.

PMID:
21943665
14.

Prevention and genetic testing for breast cancer: variations in medical decisions.

Bouchard L, Blancquaert I, Eisinger F, Foulkes WD, Evans G, Sobol H, Julian-Reynier C.

Soc Sci Med. 2004 Mar;58(6):1085-96.

PMID:
14723904
15.

The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

Hartmann LC, Lindor NM.

N Engl J Med. 2016 Feb 4;374(5):454-68. doi: 10.1056/NEJMra1503523. Review. No abstract available.

PMID:
26840135
16.

Choices--and uncertainties--for women with BRCA mutations.

Couzin J.

Science. 2003 Oct 24;302(5645):592. No abstract available.

PMID:
14576419
17.
18.

Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.

Roukos DH, Briasoulis E.

Nat Clin Pract Oncol. 2007 Oct;4(10):578-90. Review.

PMID:
17898808
19.
20.

JAMA patient page. BRCA genes and breast cancer.

Pluta RM, Golub RM.

JAMA. 2011 Jun 1;305(21):2244. doi: 10.1001/jama.305.21.2244. No abstract available.

PMID:
21632489

Supplemental Content

Support Center